case_images: PMC6907049_01
case_images: Electroencephalography before everolimus treatment (a) and after everolimus treatment (b).
case_images: CRIPE2019-2070619.001.jpg
case_images: PMC6907049_01_CRIPE2019-2070619.001.jpg
case_images: fig1
case_images: MRI finding of a subependymal nodule (SEN) (white arrow).
case_images: CRIPE2019-2070619.002.jpg
case_images: PMC6907049_01_CRIPE2019-2070619.002.jpg
case_images: fig2
case_images: At seven years of age, MRI revealed a subependymal nodule (SEN) (Figure 2).
case_images: Changes of total scores of (a) SRS and ABC and (b) SCQ and ADOS during everolimus treatment.
case_images: CRIPE2019-2070619.003.jpg
case_images: PMC6907049_01_CRIPE2019-2070619.003.jpg
case_images: fig3
case_images: The ABC is intended to evaluate treatment responses in psychopharmacological and behavioral intervention trials for children and adolescents with normal intelligence quotient (IQ) levels.  Figure 3 shows the total scores on the SRS, ABC, SCQ, and ADOS. The patient had a total score of 16.0 on the ADOS module 2 algorithm, which was greater than the average total ADOS score (8.94 +- 9.71) reported in 33 adolescents with high-functioning ASD.